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ABSTRACT
The MBD2-NuRD (Nucleosome Remodeling and
Deacetylase) complex is an epigenetic reader of DNA
methylation that regulates genes involved in nor-
mal development and neoplastic diseases. To delin-
eate the architecture and functional interactions of
the MBD2-NuRD complex, we previously solved the
structures of MBD2 bound to methylated DNA and a
coiled-coil interaction between MBD2 and p66 that
recruits the CHD4 nucleosome remodeling protein
to the complex. The work presented here identifies
novel structural and functional features of a previ-
ously uncharacterized domain of MBD2 (MBD2IDR).
Biophysical analyses show that the MBD2IDR is an
intrinsically disordered region (IDR). However, de-
spite this inherent disorder, MBD2IDR increases the
overall binding affinity of MBD2 for methylated DNA.
MBD2IDR also recruits the histone deacetylase core
components (RbAp48, HDAC2 and MTA2) of NuRD
through a critical contact region requiring two con-
tiguous amino acid residues, Arg286 and Leu287. Mu-
tating these residues abrogates interaction of MBD2
with the histone deacetylase core and impairs the
ability of MBD2 to repress the methylated tumor sup-
pressor gene PRSS8 in MDA-MB-435 breast cancer
cells. These findings expand our knowledge of the
multi-dimensional interactions of the MBD2-NuRD
complex that govern its function.
INTRODUCTION
Epigenetic regulation comprises heritable changes in gene
expression most commonly brought about by DNA methy-
lation and histone modifications. The predominant form
of DNA methylation in mammals involves addition of a
methyl group to the C5 carbon of the cytosine residue
in a cytosine-guanine dinucleotide (CpG) through the en-
zymatic activity of DNA methyl-transferases, DNMT1,
DNMT3A and DNMT3B (1). Regions of high CpG den-
sity are often associated with gene promoters (2), which
remain unmethylated except for a subset of tissue-specific
genes involved in normal differentiation and development
(3–6). Aberrant hypermethylation of tumor suppressor gene
promoters is associated with oncogenesis in a wide array of
tissues (7). The methyl-CpG binding domain (MBD) fam-
ily proteins recognize this methylated mark and repress the
associated genes by recruiting different co-repressor com-
plexes. The MBD family of proteins include the first identi-
fied MeCP2 (8) and MBD1, MBD2, MBD3 and MBD4 (9).
With the exception of mammalian MBD3, all MBD pro-
teins bind to methylated DNA although with varying affini-
ties (10–13).
MBD2 binds densely methylated CpG islands and re-
presses transcription of the associated genes through re-
cruitment of the Nucleosome Remodeling and Deacetylase
(NuRD) co-repressor complex (14). The MBD2-NuRD co-
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repressor complex from both cell lines and primary cells has
been characterized and is comprised of at least one copy
each of the MTA1/2/3, HDAC1/2, RbAp46/48, p66/,
and CHD3/4 and MBD2 proteins (5,14–16). Recent stud-
ies have evaluated the stoichiometry of protein interactions
in the NuRD complex (15,16), however much remains to be
explored about the nature and assembly of protein–protein
interactions within this complex. Previous work in our labo-
ratory identified MBD2 as a silencer of the chicken  -globin
gene (5,17,18) as well as murine and human embryonic and
fetal -type globin genes in adult erythroid cells (4,18,19).
In addition, MBD2 has been implicated in aberrant silenc-
ing of methylated tumor suppressor genes in carcinogenesis
(20–26).
The MBD2 protein consists of an N-terminal glycine-
arginine repeat region (GR), a methyl-binding domain
(MBD) which binds in vivo to densely methylated DNA
(27), an uncharacterized domain of MBD2 (MBD2IDR) and
a coiled-coil domain. In previous work we showed that the
C-terminal coiled-coil of MBD2 binds to the p66 com-
ponent of NuRD, which contributes to the recruitment
of CHD4 and gene silencing. Consistent with these find-
ings, the p66 coiled-coil domain peptide can bind to na-
tive MBD2 in cells and relieve MBD2-mediated repres-
sion of target genes such as the embryonic and fetal -type
globin genes in adult erythroid cell culture systems (18).
This proof-of-concept study underscored the biological sig-
nificance of functional disruption of the MBD2-NuRD co-
repressor complex and led us to pursue characterization of
other MBD2 mediated interactions within the NuRD com-
plex.
Intrinsically disordered proteins (IDPs) are a rapidly ad-
vancing area of research due to their importance in human
biology. Although IDPs lack a stable three-dimensional
structure under physiological conditions, they can serve
as hubs of multi-protein interactions for diverse cellular
functions including transcription regulation, chromatin re-
modeling and cell signaling because the intrinsic disorder
permits transient, low affinity but high specificity protein–
protein and nucleic acid-protein interactions (28). Among
the MBD protein family members, the transcription repres-
sion domain of MBD1 (29) and 60% of full-length MeCP2
protein have been shown to be intrinsically disordered (30),
even in the presence of their binding partners.
Having previously determined the structures of the MBD
and coiled-coil domains of MBD2, we present here the
unique structural and functional features of the previously
uncharacterized MBD2IDR. We show that this region is in-
trinsically disordered in isolation and in the context of the
full-length protein bound to DNA, we identify its role in
modifying kinetics and affinity of DNA-binding, and map
the critical sites needed for MBD2IDR to recruit the histone
deacetylase core complex within the context of the intact
MBD2 protein in cells. We anticipate these results will fa-
cilitate efforts for further biochemical and structural char-
acterization of the MBD2-NuRD complex and open up
avenues to target co-repressor activities of MBD2-NuRD
via disruption of MBD2IDR-mediated interactions with the
NuRD complex.
MATERIALS AND METHODS
Protein expression and purification
Various MBD2 constructs (Figure 1a) were cloned into a
modified pET32a vector (31) including: the MBD2IDR of
human (amino acids 238–356) and mouse (amino acids
241–359) MBD2; a human single-chain coiled-coil do-
main construct (scMBD2-p66) comprised of the MBD2
coiled-coil domain (amino acids 361–393), a short GGSG
linker, and the p66 coiled-coil domain (amino acids 137–
178); human MBD2MBD construct comprised of the iso-
lated MBD (amino acids 150–214), and a slightly longer
construct that incorporates the MBD through the first
twenty amino acids from the MBD2IDR (amino acids 150–
260), and a full-length human MBD2 single-chain con-
struct (MBD2FLsc) comprised of MBD2 (amino acids
150–393) and the scMBD2-p66. Note that the full-length
construct does not incorporate the N-terminal GR re-
peat region unique to mammalian MBD2 proteins. The
resulting plasmids were transformed into the Rosetta II
(DE3) (Invitrogen) E. coli strain, grown in either Luria
Bertani medium (unlabeled) or M9 minimal media (13C,
15N, ±2H labeled) and induced with 1mM isopropyl--d-
thiogalactopyranoside at an A600 ∼ 0.8 for 2 or 4 h, re-
spectively. Bacterial pellets from 1L of growth media were
lysed with 30 ml of the B-PER reagent (Thermo Scien-
tific) and the expressed fusion protein purified by nickel
affinity chromatography. For analytical ultracentrifugation
studies and DNA binding affinity studies, the fusion pro-
tein was further purified by gel filtration chromatography
(Superdex-75 26/60, GE Healthcare). For circular dichro-
ism (CD) and nuclear magnetic resonance (NMR) stud-
ies, the MBD2IDR and scMBD2-p66 were separated from
the thioredoxin fusion domain by thrombin cleavage at
room temperature overnight, and further purified by gel fil-
tration (Superdex-75 26/60, GE Healthcare) and ion ex-
change (MonoS 10/100, GE Healthcare) chromatography.
The final protein concentration was determined by UV ab-
sorbance at 280 nm.
MBD2FLsc:DNA complex preparation
Complementary 17 base pair oligonucleotides con-
taining a central methylated CpG dinucleotide (5′-
GAGGCGCT(meC)GGCGGCAG-3′) were purchased
from Integrated DNA Technologies (IDT), annealed
and purified by ion exchange chromatography (MonoQ
10/100, GE Healthcare) as described previously (32). The
concentration of purified double-stranded oligonucleotide
was determined by UV absorbance at 260 nm and the
DNA added in 10% molar excess to purified uniform 2H,
13C, 15N-labeled MBD2FLsc. The resulting complex was
concentrated and buffer exchanged into NMR buffer (see
below).
Surface plasmon resonance (SPR) analysis
3′ biotinylated forward oligonucleotide was purchased from
IDT, annealed to the reverse strand and purified as de-
scribed above. Protein and DNA samples were buffer ex-
changed into 10 mM HEPES pH 7.4, 50 mM NaCl, 3 mM
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Figure 1. The MBD2IDR of MBD2 is intrinsically disordered in isolation. (a) A schematic diagram shows the domain organization of the different con-
structs used in these studies including the methyl-cytosine binding domain (MBD), intrinsically disordered region (IDR), and coiled-coil (CC) domains
as well as a single chain (sc) construct that includes a short GGSG linker and the coiled-coil domain (CR1) of p66. (b) An overlay of 15N-HSQC spectra
for the MBD2IDR of HsMBD2 (red) and MmMBD2 (blue) shows a lack of chemical shift dispersion with highly degenerate Gln and Asn 15N-1H2 (blue
circle) and Trp 15N-1H (inset) resonances. (c) CD spectra of the MBD2IDR at 25◦C for HsMBD2 (black) and MmMBD2 (red) show little evidence of
secondary structure formation while a thermal melt for HsMBD2 MBD2IDR (blue) fails to reveal a cooperative transition characteristic of folded do-
mains. (d) Fitting analytical ultracentrifugation sedimentation velocity data to a continuous size distribution (SEDFIT software (35)) indicates that the
HsMBD2IDR is largely monomeric at 20 M (black) but does show evidence of slight oligomerization and aggregation at 100 M (red) concentration. (e)
PONDR R© VLXT analysis of the MBD2IDR is plotted in the upper panel which shows two sub-regions of low disorder propensity (indicated by horizontal
double-headed arrows, amino acids 240–262 and 280–308) within the IDR. Secondary chemical shifts were calculated for the MBD2IDR as described by
Kjaergaard and Poulsen (41) and plotted for alpha (13C) and carbonyl (13C’) resonances in the second and third panels. Regions with positive secondary
chemical shifts consistent with -helix formation are indicated with light blue ovals. Large red dots indicate the location of mutations that disrupt binding
to the NuRD HDCC. Heteronuclear 15N-1H NOE for the MBD2IDR are plotted in the lower panel showing that most of the domain is highly dynamic
with values < 0.5. The vertical dotted lines in all four panels indicate the three different sub-regions used for mapping the interaction with the NuRD
HDCC. The second sub-region contains a stretch of positive heteronuclear NOE values consistent with a propensity to form -helices.
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MgCl2, 0.1 mM EDTA, 1 mM DTT. SPR analysis of bind-
ing was performed on a Biacore T100 (GE Healthcare) as
described previously (10,33). The purified DNA was bound
to a Sensor SA chip (10 ng/ul DNA, 10 ul/min flow rate,
100 s) until a final relative response of approximately 100
U. Kinetic binding analyses were carried out at a flow rate
of 30 ul/min (10mM HEPES, 50mM NaCl, 3mM MgCl2,
0.1mM EDTA, 1mM DTT, 0.05% polysorbate 20, pH 7.4)
and the data were fit using the manufacturer’s software.
As described previously, the rapid on and off-rates for the
isolated MBD2MBD precluded analysis of binding kinetics.
Therefore, the binding constant for MBD2MBD was deter-
mined by steady-analysis (10,33).
Fluorescence polarization (FP) analysis
3′ FAM labeled reverse strand oligonucleotide was pur-
chased from IDT, annealed to the forward strand and pu-
rified as described above. Protein and DNA samples were
buffer exchanged into 10 mM HEPES pH 7.5, 3 mM
MgCl2, 0.1 mM EDTA, 1 mM DTT, and 0.02% sodium
azide with either 50 mM NaCl (low salt buffer) or 150
mM NaCl (high salt buffer). Serial dilutions of protein
were added to 10 mM DNA and fluorescence polarization
measured on a PHERAstar FS microplate reader (BMG
Labtech). The dissociation constant (KD) was determined
for each by fitting the observed polarization ([mP]) to a gen-







([mP]sat − [mP]DNA) ,
in which [D] and [P] are the DNA and protein concentration
and [mP]DNA and [mP]sat are the polarization for free and
protein saturated DNA, respectively. The data were fit and
plotted using Pro Fit software (QuantumSoft).
Analytical ultracentrifugation
Protein was buffer exchanged into 20mM Tris pH 8.0, 150
mM NaCl and sedimentation velocity analyzed at 40 000
rpm, 20◦C on a Beckman Optima XL-I analytical ultracen-
trifuge (Beckman Coulter Inc.) equipped with a four and
eight-position AN-60Ti rotor. Sedimentation profiles were
recorded for 20 M and 100 M samples using UV absorp-
tion (280 nm) and interference scanning optics. The sam-
ple partial specific volume, buffer density and viscosity were
calculated with the SEDNTERP (34) software and the ef-
fective molecular weight determined by fitting the data to
a continuous size distribution with the SEDFIT (35) soft-
ware.
Circular dichroism
The MBD2IDR was buffer exchanged into 10 mM NaPO4,
pH 6.5 at a final concentration of ∼100 g/ml protein. CD
spectra were collected from 185 to 260 nm (0.5 nm interval,
24 nm/min, 0.1 cm path length, 25◦C) on a ChirascanTM-
plus CD spectrometer (Applied Photophysics). CD spectra
were normalized to provide mean residue molar ellipticity
([] MRW) in degrees cm−2 dmol−1 residue−1. Helical con-
tent for each peptide was calculated as described previously
(36,37). The temperature dependence of circular dichroism
(thermal melt) was followed by measuring ellipticity at 222
nm at 1◦C intervals over a temperature range of 10–94◦C
with a heating rate of 1◦C /min.
Nuclear magnetic resonance
Uniform 13C, 15N labeled protein was buffered ex-
changed into 10 mM NaPO4, pH 6.5, 0.02% sodium
azide, 1mM dithiothreitol, and 10% 2H2O and concen-
trated to 0.5–1 mM. NMR spectra were collected on a
Bruker Avance III 700 MHz instrument at 25◦C, and
data were processed and analyzed with NMRPipe (38)
and CcpNmr (39), respectively. Standard double and
triple resonance experiments (15N-HSQC, HNCO, HN-
CACB, CBCA(CO)NH, HBHA(CO)NH, HN(CA)NNH,
HNCACO, CCH-TOCSY, (H)CC(CO)NH, 15N-NOESY-
HSQC) were collected and the backbone and sidechain
H/ resonances assigned for mouse MBD2IDR. The
1H chemical shifts were referenced to a separate sam-
ple of 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS)
prepared in NMR buffer, while 13C and 15N chemical
shifts were indirectly referenced using the IUPAC-IUB
recommended ratios (40). Given the sequence identity
and similar 15N-HSQC spectra, only HNCO, HNCACB,
CBCA(CO)NH, HBHA(CO)NH and 15N-NOESY HSQC
triple resonance spectra were necessary to propagate back-
bone and sidechain H/ resonance assignments to human
MBD2IDR. For secondary chemical shift analyses, random
coil chemical shifts for the MBD2IDR were calculated using
the webserver at http://spin.niddk.nih.gov/bax/nmrserver/
Poulsen rc CS/ (41).
1H/15N heteronuclear steady-state NOE spectra for hu-
man MBD2IDR were collected with and without 3 s of ini-
tial proton saturation in an interleaved fashion with spectral
widths of 9800 Hz over 626 complex points in 2 (1H) and
1560 Hz over 256 complex points in 1 (15N).
15N-TROSY-HSQC, TROSY-HNCO and 15N-NOESY-
HSQC spectra were collected for a ∼1mM sample of
uniform 2H, 13C, 15N-MBD2FLsc bound to methylated
DNA. Once corrected for the spin state selective J-coupling
offset, the HNCO spectra were very similar between
MBD2IDR and MBD2FLsc such that backbone amide res-
onances could be assigned for most of the IDR region of
MBD2FLsc (88 out of 110 amide resonances). Based on
these assignments, the weighted chemical shift distance in
ppm was calculated as  =
√
(0.1 ∗ δN)2 + δ2HN .
Cell culture
Human embryonic kidney 293T cells were maintained in
Dulbecco’s modified Eagle’s Medium (DMEM) contain-
ing 10% heat inactivated fetal bovine serum (Hyclone),
2mM L-glutamine and 100 U/ml penicillin and strepto-
mycin. MDA-MB-435 breast cancer cells were maintained
in DMEM supplemented with 10% heat inactivated fetal
bovine serum and 100 U/ml penicillin and streptomycin.
Cells were cultured at 37◦C and 5% CO2.
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Co-immunoprecipitation
Various MBD2 constructs were cloned into the pCMV-
Tag2B (Stratagene) vector in frame with an N-terminal flag-
tag sequence. HEK 293T cells were transfected with the re-
sulting vectors (18 g plasmid DNA) by calcium phosphate
precipitation method (42) and harvested after 48 h. Cells
were lysed and immunoprecipitated with anti-flag M2 an-
tibody (Sigma) and mouse IgG (Santa Cruz) controls ac-
cording to the Sigma Flag-IPT kit protocol (Sigma-Aldrich,
Inc., St. Louis, MO, USA). The precipitated proteins were
then analyzed for different components of the MBD2-
NuRD complex by western blot using antibodies against
RbAp48 (Abcam ab79416), HDAC2 (Millipore #05–814)
and MTA2 (Santa Cruz sc-28731).
For full-length MBD2 pull downs, the cells were lysed
in micrococcal nuclease (MNase) digestion buffer (25mM
HEPES-KOH pH 7.6, 100mM NaCl, 5mM MgCl2, 3mM
CaCl2, 10% glycerol, 0.2% NP40 and 1X EDTA-free pro-
tease inhibitor cocktail (Roche)) followed by MNase diges-
tion using 1500 U/ml of MNase (Worthington Biochemi-
cal, Lakewood, NJ, USA) for 2 h on ice. Ethidium bromide
was then added to the lysate at 300 g/ml followed by a spin
at 10 000xg for 15 mins at 4◦C. The supernatant was then
subjected to immunoprecipitation as previously described.
Site-directed mutagenesis
Mutant oligonucleotides targeting the conserved residues of
the 1st and 2nd region of MBD2IDR were designed using the
QuikChange Primer Design Program (www.agilent.com/
genomics/qcpd). Primers used for mutagenesis are listed in
Supplementary Table S1. Mutagenesis was carried out per
manufacturer’s protocol using the Quikchange Lightning
Site-Directed Mutagenesis Kit (Agilent Technologies, Inc.,
Santa Clara, CA, USA). Clones were verified by sequencing
and used for transfections.
Sequence alignments
Protein-coding sequences of MBD2 for different species
were obtained from the NCBI Protein database and
aligned using the PRALINE software (http://www.ibi.vu.
nl/programs/pralinewww/).
Local isoelectric point calculation
Each residue (i) in the protein was assigned a local iso-
electric point (pI) calculated from the amino acid sequence
(43) for residues spanning i ± 7. The pI was calculated us-
ing the SeqUtils.IsoelectricPoint module in the Bio pack-
age from the Biopython Project (www.biopython.org). For
those residues less than seven from the N- or C-termini,
the isoelectric point was calculated from the amino acid se-
quence for residues spanning i ± n where n is the number of
residues between i and the N- or C- terminus.
Lentiviral knockdown and expression of MBD2
The shMBD2 (5′ - GGGTAAACCAGACTTGAA - 3′) se-
quence was cloned into the pRRL.H1.shRNA vector. Full-
length wild-type and mutant MBD2 gene sequences were
cloned in the pLV203 vector with a flag-tag added to the C-
terminus (Genecopoeia, Rockville, MD, USA). Both full-
length MBD2 genes contain a single silent mutation in-
troduced into the MBD2 shRNA target sequence to con-
fer shRNA resistance. The vectors were packaged into a
lentivirus by calcium phosphate transfections of HEK 293T
cells. MDA-MB-435 breast cancer cells were transduced
with packaged virus and grown in vitro for 7 days post-
transduction before quantitative polymerase chain reaction
and western blot analyses. Protein concentrations of cell
lysates were measured using the BioRad DCTM Protein As-
say. The MBD2 protein was quantified on western blots
with the LI-COR Odyssey R© Infrared Imaging System using
the Image Studio Software based on Chemi-luminescence
imaging. Primers used for qPCR analysis are listed in Sup-
plementary Table S2. Antibodies used for MBD2 and Flag
epitope protein detection were from Santa Cruz (sc1244)
and Abcam (ab1162), respectively. All lentiviral vector in-
fection experiments were repeated independently at least
three times and a paired Student’s t-test used to compare
repression of gene expression.
RESULTS
The MBD2IDR region is intrinsically disordered
We cloned, expressed and purified from bacteria the
MBD2IDR from both the human (amino acids 238–356) and
mouse (amino acids 241–359) MBD2 proteins (Figure 1a).
The 2D 15N-HSQC spectra of each (Figure 1b) show fea-
tures characteristic of a disordered peptide. The amide
backbone resonances are quite sharp, the 1H(N) chemical
shifts fall between 7.5 and 8.5 ppm, and the sidechain amide
resonances are highly degenerate. In particular, the 1H-15N
resonances of two Trp residues completely overlap (inset,
Figure 1b), while seven Asn and ten Gln sidechain 15N-
1H2 resonances overlap extensively (blue dashed oval, Fig-
ure 1b). These findings indicate that the MBD2IDR domain
remains largely disordered in solution.
We further characterized this region by CD and analyti-
cal ultracentrifugation. The CD spectra are consistent with
a highly disordered peptide comprised of only 9% helix at
25◦C (Figure 1c) based on mean residue molar ellipticity
([] MRW) at 222 nm. The temperature dependence for CD
at 222 nm did not show a cooperative transition typical of
a folded domain (blue curve, Figure 1c). Sedimentation ve-
locity by analytical ultracentrifugation analysis is consistent
with a monomeric protein at 20 M with a tendency to ag-
gregate at higher concentrations (Figure 1d).
Although the backbone resonances of the MBD2IDR
lack significant chemical shift dispersion, we were able to
assign these resonances using standard 3D heteronuclear
techniques. The mouse domain was particularly well be-
haved, such that we first assigned mouse MBD2IDR and
then carried those assignments over to the human protein.
Based on these assignments, secondary chemical shifts were
calculated for the MBD2IDR (41) and plotted for alpha
(13C) and carbonyl (13C’) carbons in Figure 1e. Three sep-
arate segments of the MBD2IDR have positive secondary
chemical shifts indicative of a propensity to form -helices
(light blue ovals, Figure 1e). For comparison, the disorder
propensity for the MBD2IDR as calculated by PONDR R©
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VLXT (Predictor of Naturally Disordered Regions) (44,45)
is plotted in the first panel of Figure 1e. This latter analy-
sis predicts that two sub-regions within MBD2IDR (amino
acids 212–273 and 274–316) have low disorder propensity
(indicated by double-headed arrows in Figure 1e). The first
two of the potential helical segments fall within the second
region of low disorder propensity, supporting the idea that
this region can adopt transient helical secondary structure
in isolation. Heteronuclear NOE values (Figure 1e, lower
panel) remain below 0.5 throughout the MBD2IDR indi-
cating a high degree of internal dynamic motion; yet, the
same region with low disorder propensity and large sec-
ondary chemical shifts (amino acids 212–316) also show
the largest heteronuclear NOE values. Therefore, these data
demonstrate that while the MBD2IDR remains largely un-
structured in isolation, the central portion has a tendency
to form -helices that may fold into a more stable structure
either in the context of full-length protein or upon binding
other components of NuRD.
To test whether the MBD2IDR depends on surround-
ing regions of the protein to adopt a regular structure, we
sought to analyze this region in the context of the surround-
ing MBD and coiled-coil domains. However, a polypeptide
including the MBD, MBD2IDR and coiled-coil domains of
MBD2 has proven difficult to purify from bacterial expres-
sion systems. We recently designed and tested a remark-
ably stable and well-behaved single chain construct of the
coiled-coil domains from MBD2 and p66 (Supplementary
Figure S1a). This single-chain construct (scMBD2-p66)
comprises the MBD2 coiled-coil domain (amino acids 361–
393), a short GGSG linker, and the p66 coiled-coil domain
(amino acids 137–178). The scMBD2-p66 retains helical
content as measured by CD analysis up to 95◦C (Supple-
mentary Figure S1b) and the 2D 15N-HSQC spectrum re-
mains dispersed even at 80◦C (Supplementary Figure S1c).
Adding the scMBD2-p66 to the MBD and MBD2IDR of
MBD2 (MBD2FLsc, amino acids 212–356) stabilizes the
protein for bacterial expression and purification.
A 2D 15N-HSQC spectrum of the MBD2FLsc protein
bound to methylated DNA contains a few broadened and
dispersed as well as many sharp and highly degenerate reso-
nances (Figure 2a). An overlay of the 2D 15N-HSQC spec-
tra (Figure 2b) for MBD2FLsc bound to methylated DNA
(red) and MBD2IDR (blue), plotted at a higher contour
level, shows that the sharp and degenerate resonances from
MBD2FLsc are similar to those of the MBD2IDR. Given
the similarity in chemical shifts and the sharpness of these
peaks, we were able to carry over assignments for 80% of
the amide resonances of the IDR in the MBD2FLsc:DNA
complex. Plotting 1H,15N chemical shift differences be-
tween resonances from the isolated MBD2IDR and the same
region in the MBD2FLsc:DNA (Figure 2d) confirm that
the chemical shifts are very similar throughout the region
( < 0.05ppm).
Comparing the broadened and more dispersed reso-
nances (Figure 2c) with those for the isolated MBD2MBD
bound to methylated DNA (teal) and coiled-coil domains
(purple) (18) shows that these peaks are attributable to the
MBD and coiled-coil domains. In previous studies we found
that the chemical shifts for Gly169 and Ala172 are quite dif-
ferent when bound to either unmethylated or methylated
DNA: Gly169 shifts from 107 ppm to 102 ppm in 15N while
the Ala172 shifts from 7.0 ppm to 7.3 ppm in 1HN, respec-
tively (10). As can be seen in Figure 2c, Gly169 and Ala172
show very similar chemical shifts for both MBD2FLsc and
MBD2MBD indicating a similar methylation specific bind-
ing mode. Together these findings show that the MBD2IDR
region remains largely disordered even in the context of full-
length protein and does not appear to affect the structure or
DNA binding mode of the MBD.
The MBD2IDR modifies DNA binding kinetics and overall
binding affinity
To determine if the MBD2IDR alters the affinity of MBD2
for DNA, we measured binding to methylated DNA by sur-
face plasmon resonance. As described previously (33), the
isolated MBD shows rapid on and off-rates, which requires
steady state analysis to determine the overall binding affin-
ity (KD = 330 nM, Figure 3a). In contrast, the MBD2FLsc
shows an ∼100-fold increase in affinity (KD = 2 nM) as com-
pared to the MBD2MBD. Inspection of the MBD2IDR re-
veals that the region just C-terminal to the MBD contains
positively charged Arg and Lys residues, which could con-
tribute to DNA binding through non-specific electrostatic
interactions. Therefore, we calculated a theoretical isoelec-
tric point for a sliding window of 15 amino acids along the
entire length of each protein. The results of this analysis
for human (Hs) MBD2 paralogs (MBD2, MBD3, MBD3-
L1 and MBD3-L2) as well as Bombyx mori (Bm) and Am-
phimedon queenslandica (Aq) MBD2 orthologs are plotted
for the region homologous to the MBD2IDR of each protein
in Figure 3b. Each of the MBD2 orthologs contains a pos-
itively charged region just following the MBD and at the
N-terminus of the MBD2IDR (Figure 3b). To test whether
this region is sufficient to modify DNA binding, we mea-
sured binding kinetics by surface plasmon resonance for
an MBD2 construct that includes the MBD and the first
20 amino acids of the MBD2IDR (residues 150–260). This
construct incorporates amino acids from the N-terminal
portion of the IDR (red bar, Figure 3b) that show evolu-
tionary conservation of a net positive charge. Similar to
MBD2FLsc, MBD2(150–260) binds with increased affinity
(KD = 20 nM) compared to the isolated MBD (Figure 3a).
To validate these findings, we measured DNA binding
affinity using a fluorescence polarization based assay (Fig-
ure 3c). Similar to the results from SPR studies, MBD2FLsc
and MBD (150–260) bind methylated DNA with ∼100-
fold greater affinity than MBD2MBD. In addition, the bind-
ing affinity for all three constructs decreases by ∼10-fold
with an increase in NaCl concentration from 50 mM to
150 mM. The latter observation is consistent with non-
specific charge interactions contributing to the overall bind-
ing affinity. Therefore, the MBD2IDR contains a positively
charged region that modifies binding kinetics and affinity
despite a lack of regular structure formation. Similar posi-
tively charged disordered regions adjacent to DNA binding
domains have been described previously and referred to as
‘fuzzy’ domains (46–48).




































































Figure 2. NMR analysis of intrinsically disordered MBD2IDR. (a) A 2D 15N-HSQC spectra of MBD2FLsc (red) bound to methylated DNA shows both
sharp and highly degenerate as well as a few broadened and dispersed resonances. (b) An overlay of 2D 15N-HSQC spectra for MBD2FLsc bound to
methylated DNA (red) and the MBD2IDR are plotted at higher contours which shows that the sharp and degenerate resonances from the MBD2FLsc are
similar to those from the MBD2IDR. This similarity is most easily appreciated when comparing the more isolated peaks from glycine residues (highlighted
with a dashed circle). (c) Expanded regions from the 2D 15N-HSQC show that the broadened and dispersed resonances from MBD2FLsc (red) align with
resonances from either the MBD2MBD bound to methylated DNA (teal) or the MBD2-p66 coiled-coil complex (purple). Likewise, two key resonances
from the MBD2MBD that show unique chemical shifts when bound to methylated DNA (Gly169 and ALa172) show similar chemical shifts in the context
of MBD2FLsc. (d) Plotting the chemical shift distance () between resonances from the isolated MBD2IDR and the same region of MBD2FLsc when
bound to methylated DNA shows only small chemical shift differences (< 0.05 ppm) throughout the region.
The MBD2IDR binds the histone deacetylase core complex of
NuRD
In previous studies we showed that the coiled-coil domain of
MBD2 recruits the p66 and CHD4 proteins to NuRD. To
investigate whether the MBD2IDR and coiled-coil domains
interact with the remaining core components of NuRD
(MTA2, HDAC2 and RbAp48), the MBD2IDR was ex-
pressed in 293T cells as a flag-tagged construct, with and
without the scMBD2-p66 coiled-coil domains (Figure 4a
and d, respectively). Cell lysates were immunoprecipitated
with an anti-flag antibody followed by western blot analysis
to identify the NuRD components interacting with the flag-
tagged MBD2IDR. Figure 4a shows that the MBD2IDR of
MBD2 strongly interacts, either directly or indirectly, with
the RbAp48, HDAC2 and MTA2 components of NuRD
while the scMBD2-p66 does not. The MBD2IDR does not
interact with p66 and CHD4 proteins (Supplementary
Figure S2) as expected, which uniquely maps the interac-
tion of MBD2 with the histone deacetylase and chromatin
remodeling components of the NuRD complex into two
distinct functional domains, the MBD2IDR and the MBD2
coiled-coil domain, respectively.
Segments of intrinsically disordered proteins can fold
upon interacting with target proteins to adopt regular sec-
ondary structure. These segments, referred to as molecular
recognition features (MoRFs)(48–50), may be identified as
regions with low disorder propensity by disorder prediction
algorithms. To identify the minimal region necessary for
binding to the histone deacetylase core complex of NuRD,
the MBD2IDR was divided into three separate sub-regions
(amino acids 212–273, 274–316 and 317–360, Figure 1e) in
order to isolate the central portion with helical and struc-
tural propensity from the N and C-terminal regions. We
tested whether each of these regions, separately and in com-
bination, could immunoprecipitate HDCC components. As
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Figure 3. The MBD2IDR modifies DNA binding kinetics and affinity. (a) Surface plasmon analysis of DNA binding shows that both MBD2FLsc (upper
panel), and MBD2(150–260) (second panel) bind with higher affinity than the isolated MBD (third panel). Steady-state analysis of the isolated MBD
binding to methylated (red) and unmethylated (blue) DNA is shown in the fourth panel. (b) The local isoelectric point, calculated as described in the text,
is plotted for the region homologous to the MBD2IDR in HsMBD2, HsMBD3, HsMBD3-L1, HsMBD3-L2, BmMBD2/3 and AqMBD2/3. A red bar
indicates the region from the N-terminus of the MBD2IDR included in the MBD2(150–260) construct, which shows that the positive charge is conserved
across the animal kingdom. (c) To validate the SPR studies, binding affinity (KD) of MBD2FLsc, MBD2(150–260) and MBD2MBD for methylated DNA was
determined by a fluorescence polarization assay. Fitting the resulting binding curves to a general two-state binding model shows that both MBD2FLsc and
MBD2(150–260) bind with ∼100-fold greater affinity than the isolated MBD2MBD. Furthermore, the binding affinity of each shows a similar dependence
on salt concentration such that increasing NaCl from 50 to 150 mM reduces the affinity by ∼10-fold.











































































Figure 4. The MBD2IDR binds the histone deacetylase core complex of
NuRD. (a) The MBD2IDR with scMBD2-p66 was transfected in high-
transfection-efficiency HEK 293T cells. Immunoprecipitation and western
blot analysis of the transfected cells indicates that the MBD2IDR binds
the histone deacetylase core components RbAp48, HDAC2 and MTA2,
whereas the scMBD2-p66 construct does not. The flag-IP lane shows pull
down of the histone deacetylase core components by immunoprecipitation
using an anti-flag antibody directed against the flag-tagged MBD2IDR.
IgG and expression vector pCMV serve as negative controls while the input
lane shows 2% of the input. (b) The MBD2IDR was divided into three sub-
regions to test whether we could isolate critical binding region(s) for the
core complex components. (c) The three sub-regions of MBD2IDR were
expressed individually in HEK 293T cells and immunoprecipitated, but
failed to bind to either of the histone deacetylase core complex compo-
nents. Note that a non-specific band appears in the IgG lane when blotted
with anti-MTA2 that runs just below the MTA2 protein in the input and
flag IP lanes. (d) The region of MBD2IDR from amino acids 212–316 com-
prising the first and second ordered sub-regions in combination can bind to
RbAp48, HDAC2 and MTA2, although a weaker interaction with MTA2
was observed.
can be seen in Figure 4c, none of these three sub-regions
interact with the core complex in isolation. However, the
first and second sub-regions of MBD2IDR in combination
(amino acids 212–316) were sufficient to bind RbAp48,
HDAC2 and MTA2, albeit with a somewhat weaker inter-
action with MTA2 as compared to the entire MBD2IDR
(Figure 4d).
Key residues within minimal MBD2IDR are evolutionar-
ily conserved: full-length protein sequences of HsMBD2 or-
thologs from across the animal kingdom (Aq, Trichoplax
adhaerans (Ta), Bm, Danio rerio (Dr), Gallus gallus (Gg),
Mus musculus (Mm)), and Hs paralogs MBD3, MBD3-
like 1 and 2 (MBD3-L1, MBD3-L2) were obtained from
the NCBI protein database. The protein sequences of in-
dividual domains of MBD2 were aligned using the default
settings of the PRALINE online server. An alignment of
the MBD (Supplementary Figure S3a) for orthologs (Aq,
Bm, Dr, Gg and Mm) and a paralog (MBD3) that con-
tain a recognizable MBD shows a high degree of conserva-
tion from sponge to human (AqMBD2 and HsMBD2 pro-
teins share 64% identity in their MBDs). Critical residues
known to influence DNA binding affinity and methyla-
tion selectivity (Tyr178 and Lys174 of HsMBD2) (10,12,13)
are highly conserved indicating that methylation specificity
likely developed with the first multi-cellular organisms. No-
tably, several homologs (Ta MBD2/3, Hs MBD3-L1 and
L2) lack an MBD, yet previous studies have shown that
both the MBD3-L1 and L2 paralogs interact with NuRD
and compete with MBD2 and MBD3 for complex forma-
tion (51–53). Therefore, NuRD complex recruitment and
DNA binding represent distinct and separable functions of
MBD2.
An alignment of the MBD2IDR and coiled-coil regions
(Supplementary Figure S3b), shows much less conserva-
tion with large insertions (i.e. TaMBD2/3 and AqMBD2/3)
and smaller deletions as compared to HsMBD2. Nonethe-
less, specific individual residues are absolutely conserved
across species suggesting that these amino acids are criti-
cal to function. Highly conserved residues were identified
within the first two ordered regions of MBD2IDR implicated
in binding to the NuRD histone deacetylase core complex.
We mutated these conserved residues individually or in pairs
as follows: (1) P244G, (2) R246E, (3) T248A, (4) P255A,
(5) V256A, (6) P278G, (7) Q280A, (8) W283A, (9) R286E,
(10) L287A, (11) L290A, (12) R246E/T248A and (13)
R286E/L287A (see red stars above the sequence alignment
in Supplementary Figure S3b). Flag-tagged MBD2IDR mu-
tants were expressed in 293T cells followed by immuno-
precipitation and blotting for components of the histone
deacetylase core complex of NuRD. Of the eleven con-
served residues tested, only two contiguous amino acids
from the second ordered region of MBD2IDR, Arg286 and
Leu287, when mutated, markedly decreased binding to the
core complex (Figure 5a). Interestingly neither of these mu-
tations in isolation nor any of the other mutations dis-
rupted binding to the histone deacetylase core components.
Next, we introduced the double mutations, R286E/L287A,
into the full-length human MBD2 gene sequence by site-
directed mutagenesis. Since MBD2-NuRD contains several
potential DNA binding proteins, the immunoprecipitation
protocol for full length MBD2Flag constructs was modi-
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Figure 5. Two conserved residues from minimal MBD2IDR are neces-
sary to bind the histone deacetylase core of NuRD. (a) Mutating five
residues from the first region of minimal MBD2IDR (P244G, R246E,
P255A, V256A and R246E/T248A) does not affect immunoprecipitation
of the histone deacetylase core complex. Similarly, mutating four residues
from the second ordered region of minimal MBD2IDR (P278G, Q280A,
R286E and L287A) does not affect immunoprecipitation of the histone
deacetylase core complex. However, combined mutation of two adjacent
residues (R286E/L287A) significantly abrogates the ability of MBD2IDR
to recruit the histone deacetylase core components. Strikingly, the indi-
vidual mutants R286E and L287A have no effect on interaction of the
MBD2IDR with the histone deacetylase core. Three additional mutations
(T248A, W283A and L290A) do not affect binding of MBD2IDR to the his-
tone deacetylase core complex (data not shown). (b) Full length flag-tagged
MBD2 carrying the double mutation R286E/L287A (Double Mutant)
also displays a disrupted interaction with RbAp48, HDAC2 and MTA2.
The interaction of Double Mutant MBD2 with MTA2 is completely lost
whereas its interaction with RbAp/HDAC shows significant reduction.
fied to eliminate contamination through non-specific DNA
binding. The cell lysate from transfected cells was treated
with micrococcal nuclease, which cleaves both single- and
double-stranded DNA and RNA, and with ethidium bro-
mide, which intercalates between stacked bases in the dou-
ble helix. As expected, immunoprecipitation of the NuRD
complex by the mutant full length MBD2 revealed impaired
interaction with the histone deacetylase core components:
RbAp48, HDAC2 and MTA2, with the effect being most
pronounced for MTA2 (Figure 5b). Together these obser-
vations indicate that Arg286 and Leu287 comprise a critical
interaction surface necessary but not sufficient for recruit-
ing the histone deacetylase core complex of NuRD.
To determine if interaction with the histone deacetylase
core components is necessary for methylation dependent
gene silencing by MBD2, we designed a repression assay to
study the functional effects of the R286E/L287A (Double
Mutant) MBD2 on expression of an endogenous gene. The
Double Mutant MBD2Flag construct was expressed in a
background of partial knockdown of endogenous MBD2
in MDA-MB-435 breast cancer cells. The percentage of re-
pression of the endogenous tumor suppressor gene PRSS8
was used to measure MBD2-NuRD mediated transcrip-
tional repression. We previously showed that 75% stable
knockdown of MBD2 by shRNA in MDA-MB-435 cells in-
creased PRSS8 expression, demonstrating that MBD2 me-
diates endogenous transcriptional repression of this gene in
these cells (20).
Concomitant knockdown of endogenous MBD2 and
enforced expression of wild-type or Double Mutant
MBD2Flag was achieved by simultaneous lentivirus me-
diated delivery of anti-MBD2 shRNA (SH) and wild-type
(WT) or Double Mutant MBD2Flag mRNA resistant to
knockdown (20). Western blotting with anti-MBD2 anti-
body (Figure 6a), which recognizes both endogenous (lower
band) and lentivirally expressed MBD2Flag (top band),
shows about 50% knockdown of the endogenous MBD2
protein in SH+WT and SH+Double Mutant cells as com-
pared to negative control cells simultaneously infected with
both a scramble short RNA sequence (SC) expression vec-
tor and an empty lentivirus (LV) expression vector. De-
spite the ability of this MBD2 shRNA construct to knock
down MBD2 levels by greater than 75% (Supplementary
Figure S4a) (20), we were unable to achieve the same
level of knockdown when cells were concomitantly infected
with lentiviral MBD2 expression constructs, regardless of
whether cells were infected with both constructs simultane-
ously or sequentially (in either order). Detection of the ex-
ogenously expressed MBD2Flag proteins with an anti-flag
antibody demonstrates similar expression levels in SH+WT
and SH+Double Mutant transduced cells, as determined
by quantitative chemiluminescence (Figure 6b). Taking into
account both knockdown of endogenous MBD2 and ex-
pression of MBD2Flag proteins, the total amount of MBD2
protein in both groups (SH+WT and SH+Double Mutant)
remains constant and represents more total MBD2 pro-
tein than in the negative control cells. Partial knockdown
of endogenous MBD2 and enforced expression of wild type
MBD2, results in approximately 70% more repression of
the PRSS8 gene than in negative control cells. However,
enforced expression of the Double Mutant MBD2 results
in a smaller increase in repression of the PRSS8 gene as
compared to the negative control cells (Figure 6c). Hence
the amount of repression of the PRSS8 gene is consis-
tently ≥2-fold higher (P-value<0.01) in SH+WT cells than
in SH+Double Mutant cells. We attribute this difference
to the inability of Double Mutant MBD2 to effectively re-
cruit the histone deacetylase core components of the NuRD
complex. The suggestion of residual repressive activity by
the Double Mutant MBD2 may reflect that it retains an in-
tact coiled-coil domain. We have shown previously that the
interaction of the coiled-coil domain with p66 and CHD4
mediates at least part of the repressive activity of MBD2-
NuRD (18).
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Figure 6. Double Mutant MBD2 shows reduced transcriptional repression
of its methylated target gene PRSS8. Western blot quantitative chemilumi-
nescence analysis of MDA-MB-435 cells infected with lentivirus for MBD2
knockdown (SH) and expression of wild-type (WT) and R286E/L287A
(Double Mutant) MBD2 shows (a) ∼50% and ∼40% knockdown of en-
dogenous full-length MBD2 in SH+WT and SH+Double Mutant cells,
respectively, and (b) equivalent expression of WT and Double Mu-
tant MBD2Flag in SH+WT and SH+Double Mutant cells, respectively.
SH+Double Mutant cells contain ∼60% mutant MBD2Flag as compared
to SH+WT cells. (c) Transcript levels of PRSS8 were measured by qPCR,
normalized to endogenous transcript levels of GAPDH, and plotted as
percent repression compared to SC+LV control cells. SH+WT cells show
significantly increased repression of PRSS8 as compared to SH+Double
Mutant cells (p < 0.01). Box plots represent three independent experi-
ments and a paired Student’s t-test used to compare repression of PRSS8
gene expression. (d) A working model of the architecture of the MBD2-
NuRD co-repressor complex maps interactions between MBD2 and the
histone deacetylase core subunits to the MBD2IDR, wherein mutation of
the two contiguous residues comprising the critical interaction site (shown
as red asterisks in the IDR) impairs binding. The previously character-
ized (CC) coiled-coil domain of MBD2 recruits the chromatin remodeler
CHD4 through p66 and the MBD recruits the co-repressor complex to
sites of dense CpG methylation.
DISCUSSION
Research over the past two decades has challenged the tra-
ditional structure-function paradigm of proteins. Instead of
adopting a well-folded three-dimensional structure in solu-
tion, many proteins are entirely disordered or contain func-
tionally important intrinsically disordered regions (IDR).
Estimates indicate that from 15% to 45% of eukaryotic pro-
teins have long (>30 amino acid) regions of disorder (28).
These regions can function either by folding upon binding
to a target ligand or through dynamic interactions involving
rapidly exchanging conformations of the disordered state
(28,46,48).
Here we show that a large segment (∼145 amino acids)
between the conserved MBD and coiled-coil domains of
MBD2 behaves as an intrinsically disordered region in
isolation and in the context of the full-length protein.
This region does not adopt a regular structure even when
bound to methylated DNA. Nonetheless incorporating the
MBD2IDR affects the binding kinetics and overall affinity
for DNA, functioning as a ‘fuzzy’ domain (46). The N-
terminal portion of the MBD2IDR has a net positive charge
that is conserved across evolution and likely contributes
to this fuzzy interaction with the DNA (see Figure 3b).
IDRs flanking functional DNA-binding domains have been
shown to influence DNA recognition and potentially rates
of association and lifetime of the DNA-protein interactions
(54,55).
IDRs are often found in proteins that serve as hubs of
one-to-many protein interactions (56–58). In this report we
demonstrate that the MBD2IDR of MBD2 binds the his-
tone deacetylase core complex of NuRD comprised of the
MTA2, HDAC2 and RbAp48 proteins. To map this interac-
tion, we divided the MBD2IDR into three potential MoRFs
based on NMR analyses of residual structure and the disor-
der propensity. We found that the first two segments of the
MBD2IDR are necessary and sufficient to bind the histone
deacetylase core complex (Figure 4d). Interestingly, this re-
gion incorporates both the positively charged segment that
contributes to DNA binding as well as the region with he-
lical propensity. We were unable to identify sub-regions of
MBD2IDR that selectively bind to different components of
the histone deacetylase core complex, which suggests coop-
erative all-or-none formation of this complex (Figure 4c).
This observation indicates that either the MBD2IDR forms a
large contact surface for binding each of the proteins coop-
eratively or that the MBD2IDR binds to one of the core com-
ponents which in turn interacts with other components. In
support of the latter interpretation, recent structural anal-
yses have shown that the ELM2 and SANT domains of
MTA1 bind directly to HDAC1 (59) and a small peptide
from the C-terminal region of MTA1 binds RbAp48 (60).
The MTA proteins may provide a common point of con-
tact such that MBD2IDR binding directly to either of RbAp,
HDAC, or MTA would be sufficient to recruit all of the hi-
stone deacetylase core components.
Intrinsic disorder in MBD2 appears to be under selec-
tive pressure as evidenced by conservation of numerous
residues within the MBD2IDR across several paralogs and
distantly related orthologs, despite large insertions and se-
quence variability (Supplementary Figure S3). Using this
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evolutionary conservation as a guide, we designed point
mutations in the first and second segments of the MBD2IDR
and found that two highly conserved residues (Arg286 and
Leu287) located within the helical region of the MBD2IDR
are critical for binding to the histone deacetylase core
complex. Mutating these residues even in the context of
full length MBD2 diminishes interaction with the histone
deacetylase core complex. A recent analysis of MBD2 alter-
native splice variants revealed that dominant isoform in em-
bryonic stem cells, MBD2c, lacks most of the C-terminus in-
cluding the MBD2IDR and the coiled-coil domains. Consis-
tent with the role of these two domains in recruiting CHD4
and the histone deacetylase core complex, MBD2c fails to
interact with any of the NuRD components and lacks re-
pressive activity (61).
MBD2-NuRD has been established as a transcriptional
repressor of embryonic and fetal -type globin genes
in primary adult erythroid cells across different species
(4,5,17,18) and of tumor suppressor genes in breast cancer
cells (20,26). We hypothesized that the Arg286 and Leu287
mutations of MBD2 that impair recruitment of the hi-
stone deacetylase core components of the NuRD com-
plex would in turn abrogate repression of methylated tar-
get genes. To test this hypothesis, we assayed the expres-
sion of a previously identified highly methylated MBD2 tar-
get gene, PRSS8, in MDA-MB-435 breast cancer cells (20).
PRSS8 encodes for prostasin, a member of the trypsin fam-
ily of serine proteases that has been implicated in inhibi-
tion of metastasis of both breast and prostate cancer cells
(62,63). A CpG-rich region in the promoter and exon 1 of
PRSS8 is heavily methylated when this gene is repressed in
MDA-MB-435 breast cancer cells (62), and demethylation
by 5-aza-2′-deoxycytidine combined with histone deacety-
lase inhibitor treatment reactivates expression of PRSS8.
In our studies, Double Mutant MBD2 protein exerts dimin-
ished repression of PRSS8 when compared to an equivalent
amount of wild-type MBD2 protein, (Figure 6c) thus con-
firming the importance of these two amino acid residues in
MBD2-NuRD function.
Our results can be summarized into a dynamic working
model for the architecture of the NuRD complex wherein
the subunits carrying the chromatin remodeling enzymatic
activities unique to the NuRD complex can be mapped
to two separate domains of MBD2: the MBD2IDR which
recruits the histone deacetylase core components and the
coiled-coil domain which recruits the chromatin remodel-
ing subunit CHD4 through its interaction with p66 (Fig-
ure 6d). Delineating the multi-protein interactions within
the MBD2-NuRD complex should enable future attempts
to decouple the distinct enzymatic activities of the complex,
in isolation or combination, to disrupt the repressive func-
tions of each and dissect their potentially independent roles
in regulating specific sets of genes.
Understanding the role of IDRs in the assembly of multi-
protein complexes like MBD2-NuRD adds valuable in-
sight to their function in epigenetic regulation. IDRs have
been well recognized as hubs for interaction of many pro-
teins due to their malleability and fluctuating structures.
MBD1-c was recently shown to selectively interact with dif-
ferent binding partners through its intrinsically disordered
transcriptional repression domain (29). Structural charac-
terization of intrinsically disordered regions of other pro-
teins such as p53 (64,65), PTP1B (66), androgen recep-
tor (67), -synuclein (68,69) and oncoprotein c-myc (70,71)
has elucidated the function of these proteins in patho-
logical pathways and lead to successful efforts developing
small molecule inhibitors for therapeutic drug targeting.
The work presented here sets the stage for further biochem-
ical and functional characterization of the MBD2-NuRD
complex and raises the possibility of selectively abrogat-
ing NuRD dependent silencing of specific sets of genes by
disrupting the MBD2IDR mediated interactions with the
HDAC complex. Exploitation of such mechanistic findings
could ultimately lead to improved treatment of hemoglobin
disorders and cancer.
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